MarketCap
Facebook
X
TelegramAnnual report 2023
added 12-13-2025
Biophytis SA Total Shareholders Equity 2011-2025 | BPTS
Annual Total Shareholders Equity Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.27 M | -8.28 M | 7.01 M | 21.2 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | -8.28 M | 5.54 M |
Quarterly Total Shareholders Equity Biophytis SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.7 M | - | - | - | 2.27 M | - | - | - | -8.28 M | - | - | - | 7.01 M | - | - | - | 21.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | -8.28 M | 5.58 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.77 | 1.27 % | $ 792 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.33 | 2.61 % | $ 257 M |  USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 1.31 | 0.85 % | $ 7.14 M |  China |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 218.02 | -1.09 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.2 | -2.74 % | $ 7.7 B |  Australia |
 |
BioVie
BIVI
|
19 M | $ 1.43 | -1.7 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
BioNTech SE
BNTX
|
1.37 B | $ 94.46 | -0.37 % | $ 27.2 B | Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.93 | 2.61 % | $ 1.26 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
212 M | $ 9.58 | 0.21 % | $ 140 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 0.28 | -1.82 % | $ 609 M |  Israel |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 14.27 | 1.28 % | $ 939 M | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 563.27 | -0.18 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.33 | 1.3 % | $ 14.6 M | USA |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 90.67 | 0.94 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.95 | -0.61 % | $ 1.46 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-739 M | $ 11.68 | 1.26 % | $ 755 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 171.54 | -1.47 % | $ 25 B | USA |
 |
Abeona Therapeutics
ABEO
|
14.8 M | $ 5.34 | -0.37 % | $ 114 M | USA |
 |
ADiTx Therapeutics
ADTX
|
497 K | $ 2.11 | -5.61 % | $ 27.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
-15.2 M | $ 3.6 | -0.55 % | $ 44 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 3.33 | 0.91 % | $ 908 M | Israel |